Tianjin Chase Sun Pharmaceutical Co.,Ltd (SHE:300026)

Market Cap	10.09B -6.1%
Revenue (ttm)	4.94B -14.6%
Net Income	18.50M -13.8%
EPS	0.01
Shares Out	3.00B
PE Ratio	545.76
Forward PE	n/a
Dividend	0.03 (0.90%)
Ex-Dividend Date	Jun 24, 2025

Volume	28,307,630
Average Volume	50,309,335
Open	3.360
Previous Close	3.350
Day's Range	3.340 - 3.390
52-Week Range	3.220 - 4.490
Beta	0.13
RSI	38.11
Earnings Date	Apr 21, 2026

About SHE:300026

Tianjin Chase Sun Pharmaceutical Co.,Ltd engages in the research and development, production, and sale of various pharmaceutical products in China and internationally. The company provides Chinese medicine formula granules, finished drugs, raw materials, medical devices and excipients, medical and health services, as well as smart supply chain for pharmaceuticals and medical devices. It serves the fields of immunity, cardiovascular and cerebrovascular diseases, respiratory system, and neurodegenerative diseases. The company was founded in 1996 ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1996
• Employees: 5,297
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300026

Financial Performance

In 2025, SHE:300026's revenue was 4.94 billion, a decrease of -14.55% compared to the previous year's 5.78 billion. Earnings were 18.50 million, a decrease of -13.85%.